COVID-19 Convalescent Plasma
Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center
Sponsor: University of Chicago
A EARLY_PHASE1 clinical study on Coronavirus, this trial is completed. The trial is conducted by University of Chicago and has accumulated 7 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Completed EARLY_PHASE1
-
Jan 2021 — Mar 2024 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting EARLY_PHASE1
▶ Show 2 earlier versions
-
Jun 2020 — Dec 2020 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting EARLY_PHASE1
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .